# A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma

> **NCT05860036** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 40 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **BIOLOGICAL:** anti-BCMA CAR-T
- **DRUG:** VRd

## Key facts

- **NCT ID:** NCT05860036
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-04-04
- **Primary completion:** 2025-06-01
- **Final completion:** 2028-03-10
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2025-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05860036

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05860036, "A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05860036. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*